We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| GW Pharm. | LSE:GWP | London | Ordinary Share | GB0030544687 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 735.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
Hot Features
Premium
RNS Number:9634R
GW Pharmaceuticals PLC
28 February 2007
Phase III Sativex(R) Data Published in Leading Neurology Journal
Data demonstrate that Sativex provides relief of spasticity for patients with
Multiple Sclerosis
Porton Down, UK, 28th February 2007 - A leading neurology journal, The European
Journal of Neurology, today reports a study showing that Sativex significantly
reduces intractable spasticity (spasms and stiffness) in people with Multiple
Sclerosis (MS).
The publication of these data follows the previous announcement of preliminary
results of this 189 patient study, which forms part of the regulatory filing for
Sativex for MS spasticity submitted in September 2006 in selected European
countries.
In the randomised, double-blind trial, led by Professor Christine Collin from
the Royal Berkshire and Battle NHS Trust, Reading, UK, Sativex demonstrated
significant superiority to placebo in reducing spasticity (p
1 Year Gw Pharmaceuticals Chart |
1 Month Gw Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
